Efficacy of Intravitreal Conbercept Injections in Macular Edema Secondary to Branch Retinal vein Occlusion

Volume 9, Issue 1, February 2024     |     PP. 1-7      |     PDF (196 K)    |     Pub. Date: May 10, 2020
DOI:    227 Downloads     1498 Views  

Author(s)

Kai Xing, Graduate School of Qinghai University, Xining ,China
Zefeng Kang, Ophthalmology Clinic, Eye Hospital of China Academy of Chinese Medical Sciences ,Beijing ,China

Abstract
Purpose: To assess the efficacy and safety of intravitreal conbercept injections in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Methods: The study included 33 patients (38 eyes) with ME secondary to BRVO who received intravitreal conbercept 0.05mL injections. The ophthalmological examination should be performed at least once a month during 6-month follow up, and central foveal thickness was measured with optical coherence tomography (OCT) to determine whether reinjection was needed. We compared the best corrected visual acuity (BCVA) between pretreatment and 1, 3 months after treatment, aslo the OCT results between pretreatment and 1 month after treatment. Moreover, we observed the occurrence of complications within 1 month after treatment.
Results: The logarithm of minimum visual acuity (VA) was 0.59 ± 0.21 at baseline, and improved to 0.35 ±0.12 after the first injection (P<0.01). The BCVA was statistically different between baseline and 1, 3 months after treatment (P<0.05), and the BCVA at 3 months after treatment was significantly higher than baseline (P<0.05). The central foveal thickness was also statistically different between baseline and 1 month after treatment (P<0.05). Only 5 patients (15.15%) had transient elevation of intraocular pressure, and no other obvious ocular adverse events were observed within 1 month after treatment.
Conclusion:Intravitreal injections of conbercept demonstrated a generally favorable short-term efficacy as well as safety in the treatment of ME due to BRVO based on OCT.

Keywords
Conbercept; Branch retinal vein occlusion ; Macular edema ; Optical coherence tomography.

Cite this paper
Kai Xing, Zefeng Kang, Efficacy of Intravitreal Conbercept Injections in Macular Edema Secondary to Branch Retinal vein Occlusion , SCIREA Journal of Clinical Medicine. Volume 9, Issue 1, February 2024 | PP. 1-7.

References

[ 1 ] Allen C H, YAO Jing. Color Atlas & Synopsis of Clinical Ophthalmology: Retina[M]. Shanghai Scientific and Technical Publishers, 2005: 101.
[ 2 ] Zhang Chengfen. Fundus Disease [M]. Version 2. Beijing: People's Medical Publishing House, 2010: 560-575
[ 3 ] ZHANG Jing, CAI Xiaojun, CHEN Xiaomin, et al. A prospective randomized clinical trial on intravitreal injection of Conbercept combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J]. Chine J Ocular Fundus Dis, 2015, 31(1): 22-26.
[ 4 ] Donati S, Barosi P, Bianchi M, et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J]. Eur J Ophthalmol, 2012, 22(4): 607-614.
[ 5 ] Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J]. PLoS ONE, 2013, 8(8): e70544.
[ 6 ] Wu Z, Zhou P, Li X, et a1. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling[J]. PLoS ONE, 2013, 8(3): e57642.
[ 7 ] Qu Yi, Wei Fengcai. Will s Eye Manual [M]. Version 5. Jinan: Shandong Branch Science and Technology Press, 2009:434 .
[ 8 ] BI Ran, JIA Caihua, YU Yue, et al. Clinical observation of conbercept in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J]. J Chifeng Univ (Nat Sci Ed), 2014, 23: 71-73.
[ 9 ] Chen C H, Chen Y H, Wu P C, et a1. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection[J]. Chang Gung Med J, 2010, 33(4): 424-435.
[ 10 ] Feng J, Zhao T, Zhang Y, et al. Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion[J]. PLoS ONE, 2013, 8(7): e68149.
[ 11 ] Pielen A, MirshahiA, Fehgen N, et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial[J]. Acta Ophthalmol, 2015, 93(1): e29-37.
[ 12 ] Tsagkataki M, Papathomas T, Lythgoe D, et al. Twenty-four-month results of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion[J]. Semin Ophthalmol, 2015, Aug 21:1-8, [Epub ahead of print].
[ 13 ] Hikichi T, Higuchi M, Matsushita T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion[J]. Br J Ophthalmol, 2014, 98(2): 195-199.
[ 14 ] SHU Zhiyu. Clinical analysis of conbercept for treating macular edema secondary to branch retinal vein occlusion[J]. Yanbian Medical Journal, 2015, 12: 47-48.